Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

The company has agreed to pay $2.2 billion to settle around 80,000 state court product liability cases alleging injury from Zantac (ranitidine), most of which had been consolidated in a Delaware ...

GSK plc (LSE/NYSE: GSK) today announced that it has reached agreements with 10 plaintiff firms who together represent 93% (approximately 80,000) of the Zantac (ranitidine) state court product ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

Get detailed information on Ranitidine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000) of the Zantac (ranitidine) product liability cases ...

葛兰素史克 在美国州法院Zantac案件中达成高达22亿美元的和解协议。 葛兰素史克公司周三表示，已与10家原告公司达成协议，这些公司占美国州法院 ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...